通化金马(000766) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥409,397,546.32, representing a 13.65% increase compared to ¥360,211,471.99 in the same period last year[3] - The net profit attributable to shareholders was ¥50,931,985.61, a decrease of 12.88% from ¥58,463,126.37 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥40,683,222.82, down 27.41% from ¥56,041,854.52 in the previous year[3] - Basic earnings per share decreased to ¥0.0527, down 12.89% from ¥0.0605 year-on-year[3] - Total operating revenue for the current period reached ¥409,397,546.32, an increase of 13.6% compared to ¥360,211,471.99 in the previous period[24] - Net profit for the current period was ¥50,644,468.36, a decrease of 13.5% from ¥58,210,800.73 in the previous period[25] - Operating profit for the current period was ¥61,418,909.01, down 8.7% from ¥67,347,487.96 in the previous period[25] - The company reported a total comprehensive income of ¥87,921,660.43 for the current period, compared to ¥57,891,059.46 in the previous period, indicating a significant increase[29] - The total profit for the current period was ¥87,708,437.06, compared to ¥57,171,332.40 in the previous period, showing an increase of 53.3%[28] Cash Flow - The net cash flow from operating activities was negative at ¥63,776,462.86, a decline of 229.58% compared to ¥49,217,259.41 in the same period last year[3] - Cash inflow from operating activities was CNY 504,928,999.19, an increase from CNY 425,445,949.41 in the previous period, representing a growth of approximately 18.6%[31] - The net cash flow from operating activities was -CNY 63,776,462.86, compared to a positive cash flow of CNY 49,217,259.41 in the previous period[31] - Cash outflows for operating activities totaled CNY 568,705,462.05, up from CNY 376,228,690.00, indicating a significant increase of about 51%[31] - The cash inflow from investment activities was CNY 285,581,457.88, down from CNY 326,334,103.86, reflecting a decrease of approximately 12.5%[32] - The net cash flow from investment activities was -CNY 51,859,490.10, compared to -CNY 188,650,757.48 in the previous period, showing an improvement[32] - Cash inflow from financing activities was CNY 30,000,000.00, a decrease from CNY 86,665,377.01 in the previous period[32] - The net cash flow from financing activities was CNY 402,932.99, down from CNY 6,843,124.89, indicating a decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,915,441,089.40, a decrease of 1.36% from ¥5,997,069,913.93 at the end of the previous year[3] - The total liabilities decreased from CNY 1,249,313,522.82 to CNY 1,117,040,229.93, a reduction of approximately 10.55%[17] - The total owner's equity increased from CNY 4,747,756,391.11 to CNY 4,798,400,859.47, reflecting a growth of about 1.06%[18] - The company's current assets rose from CNY 891,819,841.71 to CNY 967,850,617.45, an increase of approximately 8.54%[20] - The non-current assets increased from CNY 3,766,797,515.22 to CNY 3,784,199,813.89, showing a growth of about 0.46%[20] - The total cash and cash equivalents at the end of the period were CNY 199,399,014.66, down from CNY 229,673,430.51[32] - The total liabilities to equity ratio improved from 1.63 to 1.47, indicating a stronger equity position[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,349[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 45.97% of the shares, totaling 444,293,544 shares[5] - The net assets attributable to shareholders increased by 1.07% to ¥4,798,400,859.47 from ¥4,747,756,391.11 at the end of the previous year[3] Government Subsidies and Other Income - The company received government subsidies amounting to ¥12,318,144.41 during the reporting period[4] - Other income increased by 187.63% due to higher government subsidies received compared to the previous year[9] Research and Development - Research and development expenses increased to ¥3,685,405.11, compared to ¥3,206,428.27 in the previous period, reflecting a growth of 14.9%[24] Investment and Equity - Investment income decreased by 149.00% due to adjustments related to the equity method for newly acquired R&D institutions[9] - Long-term equity investments increased by 30.44% due to the acquisition of equity in Beida Shijia[9] - The company achieved an investment income of ¥97,770,934.63, up from ¥49,739,720.21 in the previous period, representing a growth of 96.5%[28] Operational Insights - The company is actively promoting a major asset restructuring to enhance profitability and improve shareholder returns[10] - The first quarter report of Tonghua Golden Horse Pharmaceutical Group Co., Ltd. is unaudited[42] - The report was released on April 26, 2019[42] - No specific financial performance metrics or user data were provided in the document[42] - Future outlook and performance guidance were not discussed in the report[42] - There were no mentions of new products or technology development in the document[42] - Market expansion and mergers or acquisitions were not addressed in the report[42] - Other new strategies were not outlined in the document[42] - The report does not include any financial figures or percentages[42] - The company did not provide any insights into operational performance or market trends[42] - The document lacks detailed analysis or commentary on the company's financial health[42]